Cargando…

Elevated Eosinophil Count Following Pembrolizumab Treatment for Non-Small Cell Lung Cancer

Immune-related adverse events (IRAEs) are a common yet problematic phenomenon in patients who are treated with immune checkpoint inhibitors (ICIs). Current research efforts have explored the exact pathophysiology of IRAEs in the clinical setting. However, a rare subset of IRAEs that is less highligh...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baroz, Angel R, Mambetsariev, Isa, Fricke, Jeremy, Pharaon, Rebecca, Tan, TingTing, Kidambi, Trilokesh, Sandhu, Karamjeet S, Koczywas, Marianna, Salgia, Ravi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349225/ https://www.ncbi.nlm.nih.gov/pubmed/34377604 http://dx.doi.org/10.7759/cureus.16266

Ejemplares similares

Small Cell Lung Cancer Transformation following Treatment in EGFR-Mutated Non-Small Cell Lung Cancer
por: Mambetsariev, Isa, et al.
Publicado: (2022)

Rapid progression of disease from immunotherapy following targeted therapy: insights into treatment management and sequence
por: Pharaon, Rebecca, et al.
Publicado: (2020)

Molecular and Clinical Features of Hospital Admissions in Patients with Thoracic Malignancies on Immune Checkpoint Inhibitors
por: Zhao, Dan, et al.
Publicado: (2021)

Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer
por: Roosan, Moom R., et al.
Publicado: (2021)

Hyperprogression on immunotherapy with complete response to chemotherapy in a NSCLC patient with high PD-L1 and STK11: A case report
por: Fricke, Jeremy, et al.
Publicado: (2020)

Role of immunotherapy and co-mutations on KRAS-mutant non-small cell lung cancer survival
por: Amanam, Idoroenyi, et al.
Publicado: (2020)

Non-Small Cell Lung Cancer from Genomics to Therapeutics: A Framework for Community Practice Integration to Arrive at Personalized Therapy Strategies
por: Rajurkar, Swapnil, et al.
Publicado: (2020)

Complex Oncological Decision-Making Utilizing Fast-and-Frugal Trees in a Community Setting—Role of Academic and Hybrid Modeling
por: Salgia, Ravi, et al.
Publicado: (2020)

The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC)
por: Salgia, Ravi, et al.
Publicado: (2021)

Co-stimulatory and co-inhibitory immune markers in solid tumors with MET alterations
por: Reckamp, Karen L, et al.
Publicado: (2020)

Evaluation of Somatic Mutations in Solid Metastatic Pan-Cancer Patients
por: Roosan, Moom R., et al.
Publicado: (2021)

Assessment of Barriers and Challenges to Screening, Diagnosis, and Biomarker Testing in Early-Stage Lung Cancer
por: Zarinshenas, Reza, et al.
Publicado: (2023)

Heuristic value-based framework for lung cancer decision-making
por: Mambetsariev, Isa, et al.
Publicado: (2018)

Predicting survival of NSCLC patients treated with immune checkpoint inhibitors: Impact and timing of immune-related adverse events and prior tyrosine kinase inhibitor therapy
por: Sayer, Michael R., et al.
Publicado: (2023)

Biomarkers in immunotherapy: literature review and future directions
por: Pharaon, Rebecca, et al.
Publicado: (2020)

Post-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancer
por: Won, Brian, et al.
Publicado: (2016)

Precision medicine and actionable alterations in lung cancer: A single institution experience
por: Mambetsariev, Isa, et al.
Publicado: (2020)

Clinical Network Systems Biology: Traversing the Cancer Multiverse
por: Mambetsariev, Isa, et al.
Publicado: (2023)

Prolonged survival and response to tepotinib in a non-small-cell lung cancer patient with brain metastases harboring MET exon 14 mutation: a research report
por: Roth, Katherine G., et al.
Publicado: (2020)

A Closer Look at EGFR Inhibitor Resistance in Non-Small Cell Lung Cancer through the Lens of Precision Medicine
por: Sattler, Martin, et al.
Publicado: (2023)

Effective osimertinib treatment in a patient with discordant T790 M mutation detection between liquid biopsy and tissue biopsy
por: Mambetsariev, Isa, et al.
Publicado: (2018)

The Association of Clinical Outcomes with Posttreatment Changes in the Relative Eosinophil Counts and Neutrophil-to-Eosinophil Ratio in Patients with Advanced Urothelial Carcinoma Treated with Pembrolizumab
por: Furubayashi, Nobuki, et al.
Publicado: (2021)

Complete response to chemoimmunotherapy with bevacizumab in synchronous multiple primary cancers: pulmonary adenocarcinoma and sarcomatoid carcinoma
por: Garcia, Diogo, et al.
Publicado: (2023)

Pembrolizumab-induced Eosinophilic Gastrointestinal Disorders
por: Nakamura, Masakatsu, et al.
Publicado: (2021)

The DNA walk and its demonstration of deterministic chaos—relevance to genomic alterations in lung cancer
por: Hewelt, Blake, et al.
Publicado: (2019)

Exosomal miRNAs species in the blood of small cell and non-small cell lung cancer patients
por: Poroyko, Valeriy, et al.
Publicado: (2018)

Eosinophilic Fasciitis following Checkpoint Inhibitor Therapy with Pembrolizumab
por: Zampeli, Evangelia, et al.
Publicado: (2021)

Modeling small cell lung cancer (SCLC) biology through deterministic and stochastic mathematical models
por: Salgia, Ravi, et al.
Publicado: (2018)

Pre-Procedural COVID Testing: The “New Normal”
por: Kidambi, Trilokesh D., et al.
Publicado: (2021)

Pyramidal Decision Support Framework Leverages Subspecialty Expertise across Enterprise to Achieve Superior Cancer Outcomes and Personalized, Precision Care Plans
por: Bosserman, Linda D., et al.
Publicado: (2022)

Anaplastic Lymphoma Kinase (ALK)-positive Tumors: Clinical, Radiographic and Molecular Profiles, and Uncommon Sites of Metastases in Patients With Lung Adenocarcinoma
por: Gupta, Rohan, et al.
Publicado: (2019)

Association Between Immune-Related Adverse Events and Efficacy and Changes in the Relative Eosinophil Count Among Patients with Advanced Urothelial Carcinoma Treated by Pembrolizumab
por: Furubayashi, Nobuki, et al.
Publicado: (2022)

HABP2 is a Novel Regulator of Hyaluronan-Mediated Human Lung Cancer Progression
por: Mirzapoiazova, Tamara, et al.
Publicado: (2015)

Machine Learning Algorithm to Perform the American Society of Anesthesiologists Physical Status Classification
por: Lew, Michael W, et al.
Publicado: (2023)

Elevated eosinophil count is related with lower anti-factor Xa activity in COVID-19 patients
por: Ari, Selma, et al.
Publicado: (2020)

Integration of artificial intelligence in lung cancer: Rise of the machine
por: Ladbury, Colton, et al.
Publicado: (2023)

Assessing the yield and safety of endoscopy in acute graft-vs-host disease after hematopoietic stem cell transplant
por: Rajan, Anand V, et al.
Publicado: (2020)

Gastrostomy tubes: Fundamentals, periprocedural considerations, and best practices
por: Rajan, Anand, et al.
Publicado: (2022)

Acquired Resistance to PD-1/PD-L1 Blockade in Lung Cancer: Mechanisms and Patterns of Failure
por: Pathak, Ranjan, et al.
Publicado: (2020)

Differential Distribution of Brain Metastases from Non-Small Cell Lung Cancer Based on Mutation Status
por: Chen, Bihong T., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_up5bhfut80pucv999bb739gqkb